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All strains of Neisseria gonorrhoeae with reduced susceptibility to ceftriaxone and cefixime (cephalosporin-
intermediate-resistant [Cephi] strains) contain a mosaic penA allele encoding penicillin-binding protein 2
(PBP 2) with nearly 60 amino acid differences compared to the sequence of wild-type PBP 2, together with a
set of resistance determinants (i.e., mtrR, penB, and/or ponA1) that are required for high-level penicillin
resistance. To define the individual contributions of these determinants to reduced susceptibility to ceftriaxone
and cefixime, we created isogenic strains containing the mosaic penA allele from the Cephi strain 35/02
(penA35) together with one or more of the other resistance determinants and determined the MICs of penicillin
G, ceftriaxone, and cefixime. The majority of cefixime resistance is conferred by the penA35 allele, with only a
small contribution coming from mtrR and penB, whereas ceftriaxone resistance is nearly equally dependent
upon mtrR and penB. Unlike high-level penicillin resistance, the ponA1 allele does not appear to be important
for Cephi. A strain containing all four determinants has increased resistance to ceftriaxone and cefixime but
not to the levels that the donor Cephi strain does, suggesting that Cephi strains, similar to high-level-penicillin-
resistant strains, contain an additional unknown determinant that is required to reach donor levels of
resistance. Our data also suggest that the original Cephi strains arose from the transformation of penA genes
from commensal Neisseria species into a penicillin-resistant strain already harboring mtrR, penB, ponA1, and
the unknown gene(s) involved in high-level penicillin resistance.
Neisseria gonorrhoeae is an obligate human pathogen that is
the etiologic agent of the sexually transmitted infection gon-
orrhea. In 2007, over 350,000 cases of gonorrhea were reported
in the United States, but it is estimated that the actual number
of infections may be nearly twice that number (5). N. gonor-
rhoeae primarily infects mucosal surfaces in the lower genital
tract, with females often being asymptomatic. If it is left un-
treated, gonorrhea can cause more serious infections, such as
pelvic inflammatory disease and disseminated gonococcal in-
fections, leading to sterility and even death. Since no vaccine is
currently available for N. gonorrhoeae, antibiotic therapy is the
mainstay for the treatment of infections.
For nearly 40 years, penicillin was the antibiotic of choice for
the treatment of gonorrhea, until resistance reached levels that
necessitated a switch to other antibiotics. Gonococci utilize two
main mechanisms of resistance: plasmid-mediated expression
of a TEM-1-like -lactamase and acquisition of chromosom-
ally mediated resistance determinants that collectively render
the organism resistant to clinically achievable levels of penicil-
lin (3). During the same time, tetracycline was also removed as
a treatment option, as strains of N. gonorrhoeae with either
plasmid-mediated expression of the protective TetM determi-
nant (21) or chromosomally mediated mutations that con-
ferred resistance to the antibiotic (17) had emerged. One of
the antibiotics used in lieu of penicillin and tetracycline, cip-
rofloxacin, was effective for several years, but resistance to this
antibiotic also emerged. In 2007, fluoroquinolones were also
removed from the recommended list of antibiotics to be
used for the treatment of gonococcal infections in the
United States (6).
The mechanisms of chromosomally mediated penicillin re-
sistance in the gonococci are complex and multifaceted. Early
studies, most notably by Sparling and colleagues (12, 30) and
Dougherty (10), demonstrated a stepwise transfer of resistance
from a penicillin-resistant strain (e.g., strain FA6140) to a
penicillin-susceptible strain (e.g., strain FA19) via DNA up-
take and homologous recombination. At least five resistance
determinants, which are mutated alleles of normal genes, have
been identified and characterized (16, 23, 25, 28, 31). Each of
these determinants incrementally increases resistance on its
own, but it is the cumulative effects of these determinants and
their synergistic interactions that result in clinical levels of
resistance. The first step in the transfer of resistance is the
acquisition of mutated alleles of the penA gene, which encodes
penicillin-binding protein 2 (PBP 2), the primary target of
penicillin for lethality. The hallmark of these penA alleles is a
single codon insertion, Asp345a, and four to eight mutations
clustered in the C terminus of the protein, which together
lower the rate of acylation of PBP 2 with penicillin G by 16-fold
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(26). The second step of transformation results from mutations
in the promoter region or the coding sequence of mtrR, a
transcriptional repressor that regulates the expression of the
MtrC-MtrD-MtrE efflux pump (and other genes [13]). mtrR
mutations result in overexpression of the efflux pump, high-
level resistance to hydrophobic agents (such as detergents and
dyes), and small (approximately twofold) increases in the MIC
of penicillin (16). The third step in resistance involves penB,
which encodes mutated alleles of the major outer membrane
porin PorB1b with amino acid substitutions in the constriction
loop that presumably decrease the influx of the antibiotic into
the periplasm (14, 23). Interestingly, the increase in resistance
conferred by penB occurs only in strains harboring a coresident
mtrR mutation, but the molecular basis for this requirement is
not completely understood (24).
Although the aforementioned determinants markedly in-
crease the MIC of penicillin G (from 0.01 to 0.75 g/ml) when
they are transformed into FA19, the MIC is still well below the
level for the clinical isolates that serve as DNA donors in
transformation experiments (MIC  4 g/ml). Moreover,
DNA from these donors is not capable of further transforming
the third-step transformant to higher levels of resistance (3, 10,
28). We demonstrated that high-level-penicillin-resistant
strains contain a ponA allele (ponA1) encoding PBP 1 with a
missense mutation (L421P) that lowers the rate of acylation
with penicillin G by approximately fourfold (28). Surprisingly,
whereas the reversion of the sequence of the ponA1 allele back
to the sequence of the wild-type ponA gene in high-level-
penicillin-resistant clinical strains decreased the MIC of peni-
cillin G twofold, replacement of the wild-type ponA allele with
ponA1 in the third-step transformant did not increase the MIC
of penicillin G. These data suggest that ponA1 does have a role
in penicillin resistance but requires an additional unknown
gene(s) to exert its phenotypic effect on resistance. All at-
tempts thus far to identify this gene(s) have been unsuccessful.
Gonococcal infections are now mostly treated with expanded-
spectrum cephalosporins, such as ceftriaxone and cefixime. Re-
cently, however, strains of N. gonorrhoeae showing intermedi-
ate-level resistance to these antibiotics have emerged, and if
(or when) they develop high-level resistance, they will pose a
major threat to public health. Thus far, treatment failures have
been reported with cefixime but not with ceftriaxone (9, 34).
Cephalosporin-intermediate resistance (Cephi) is chromo-
somally mediated, and the mechanisms resemble those for
chromosomally mediated penicillin resistance. The hallmark of
Cephi strains is the presence of mosaic penA alleles, which
encode PBP 2 variants with 50 to 60 amino acid changes com-
pared to the sequence of the wild-type allele. These mosaic
alleles were generated by recombination of regions of the penA
genes from N. sicca, N. perflava, N. cinerea, and/or N. flavescens
into the gonococcal penA gene (1). Aside from penA, however,
the genetics of Cephi have not been comprehensively studied
and are mostly unknown. In the present study, we examined
the roles of the mtrR, penB, and ponA1 alleles in increasing
resistance to ceftriaxone and cefixime. Our data reveal that the
mechanisms by which strains have increased resistance to the
two cephalosporins are different but that both require the pres-
ence of the unknown determinant(s) necessary for high-level
penicillin resistance.
MATERIALS AND METHODS
Strains and plasmids. The strains and plasmids used in this study are shown
in Table 1. FA19 (a penicillin- and cephalosporin-susceptible laboratory strain)
and FA6140 (a high-level-penicillin-resistant isolate) were obtained from Fred
Sparling, University of North Carolina at Chapel Hill. Strain 35/02 (a penicillin-
resistant and Cephi strain) was isolated in Sweden in 2002 (19). pUC18us-penA35
TABLE 1. Bacterial strains used in this study
Plasmid or strain Description Reference
Plasmids
pUC18us-penA35 Plasmid containing the penA35 gene from strain 35/02 7
pPR16 Plasmid containing the wild-type ponA gene and a downstream  resistance cassette
conferring spectinomycin and streptomycin resistance
28
pPR17 pPR16 with the ponA gene replaced by the ponA1 gene harboring an L421P mutation 28
pMO-porBFA1090-erm Plasmid containing the porB1b gene from FA1090 (i.e., wild-type porB1b) with a
downstream erm cassette conferring erythromycin resistance
23




FA19 Clinical isolate 20
FA6140 Clinical isolate 8
35/02 Clinical isolate 19
FA19 penA35 FA19 transformed with pUC18us-penA35 This study
FA6140 penA35 FA6140 transformed with pUC18us-penA35 This study
FA19 penA35 mtrR FA19 penA35 transformed with mtrR35/02 PCR product This study
FA19 penA35 mtrR penB35 FA19 penA35 mtrR transformed with porB1b35/02 PCR product This study
FA19 penA35 mtrR penB35 ponA1 FA19 penA35 mtrR penB35 transformed with pPR17 This study
FA6140 mtrD::Kan FA6140 transformed with pBS-mtrD::Kan This study
FA6140 penA35 mtrD::Kan FA6140 penA35 transformed with pBS-mtrD::Kan This study
35/02 mtrD::Kan 35/02 transformed with pBS-mtrD::Kan This study
FA6140 penA35 porB1bFA1090 FA6140 penA35 transformed with pMO-porB1bFA1090 This study
FA6140 penA35 ponAwild type FA6140 penA35 transformed with pPR16 This study
35/02 ponAwild type 35/02 transformed with pPR16 This study
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contains the penA gene from strain 35/02, along with 300 bp of downstream
sequence and an uptake sequence (11) to facilitate homologous recombination.
Transformants harboring the mosaic penA allele were selected with 0.02 g/ml
(strain FA19) or 0.08 g/ml (strain FA6140) cefixime. The transfer of mtrR from
strain 35/02 was accomplished by selecting transformants on 1 mg/ml Triton
X-100, and penB35 transformants were selected on 0.37 g/ml penicillin G; both
of these transformations were accomplished with PCR-amplified fragments. The
mtrR gene and promoter from strain 35/02 contain both a G45D mutation in the
coding sequence of MtrR, which disrupts the DNA-binding domain of the MtrR
repressor, and an A deletion (A) in the 13-bp inverted repeat in the mtrR
promoter (19). The A deletion results in maximal transcription of mtrCDE,
whereas the G45D mutation, when it is present by itself, also increases the level
of mtrCDE transcription, albeit to a lower level than the promoter mutation (35).
pMO-porB1bFA1090, which was used to revert penB back to porB1b, contains a
2-kb fragment of the porB1b gene from strain FA1090 (porB1bFA1090) with an
erythromycin resistance cassette downstream of the gene to aid with selection.
Plasmids pPR16 and pPR17, which harbor the coding regions of the wild-type
and mutant ponA genes, respectively, have an extra 546 bp of downstream
sequence to facilitate homologous recombination and the  fragment encoding
spectinomycin and streptomycin resistance (27) inserted 68 bp downstream of
the ponA stop codon to aid with selection (28).
Transformation. Transformation experiments were carried out essentially as
described by Ropp et al. (28). Briefly, piliated colonies of the recipient strain
were passaged on a fresh GC medium base (GCB) agar plate and grown for 16
to 20 h. The cells were swabbed from the plate; resuspended in GCB broth with
supplements I and II (18), 20 mM bicarbonate, and 10 mM MgCl2; and diluted
to an optical density at 560 nm of 0.18. Cells (0.9 ml) were incubated for 5 h at
37°C in a CO2 incubator with 10 l of a PCR product or plasmid (3 to 5 g),
and aliquots of the cells were plated on GCB agar plates containing the appro-
priate antibiotics and allowed to grow overnight. Transformants were passaged
on GCB agar plates, and the next day, colonies were boiled in 30 l of water and
spun briefly to pellet the debris. Two microliters of the supernatants was used as
the template in a PCR, and transformants showing correct recombination were
identified by sequencing.
MIC measurements. The MICs of penicillin G, ceftriaxone, and cefixime
were determined as described previously (28). Briefly, nonpiliated colonies were
streaked on a GCB agar plate and allowed to grow for 18 h. The cells were
swabbed into 2 ml of GCB broth with supplements I and II (16), 20 mM sodium
bicarbonate, and 10 mM MgCl2 and diluted to an optical density at 560 nm of
0.18. Five microliters of the cell suspension (50,000 cells) was spotted on a
series of plates containing the following ranges of concentrations of antibiotics in
approximately 1.5-fold increments: penicillin G, 0.008 to 8 g/ml; ceftriaxone,
0.0004 to 0.4 g/ml; and cefixime, 0.0004 to 0.8 g/ml. The less than twofold
increases for most concentrations in the series allowed a more accurate evalua-
tion of the MICs. At least two colonies (and often up to four colonies) from each
transformation, verified by PCR amplification and sequencing, were examined
for growth on antibiotic plates. At least three independent MIC experiments
were carried out, and the MICs reported here represent the averages of all
experiments. Error bars in the figures represent the variations of the three
determinations.
RESULTS
Role of mosaic penA allele in Cephi. To examine directly the
contribution of the mosaic penA allele to intermediate-level
resistance to ceftriaxone and cefixime, we transformed FA19, a
-lactam antibiotic-susceptible strain, and FA6140, a high-
level-penicillin-resistant clinical isolate, with the mosaic penA
gene (penA35) from the Cephi strain 35/02, which was isolated
in Sweden in 2002 (19). Upon recombination of penA35 into
FA19, the MIC of penicillin G increased from 0.012 g/ml to
0.13 g/ml, a 10-fold increase (Fig. 1). The MIC of FA19
penA35 was twofold higher than the MIC for FA19 trans-
formed with the penA gene (penA4) from FA6140 (MIC  0.06
g/ml), which harbors the Asp345a insertion and four C-ter-
minal mutations (24, 26). When the penA35 allele was trans-
formed into FA6140, the MIC of penicillin G increased two-
fold, from 3 to 6 g/ml, consistent with the twofold difference
in MICs between FA19 penA4 and FA19 penA35. Upon acqui-
sition of penA35, the MIC of ceftriaxone increased 20-fold in
FA19 (from 0.0006 to 0.012 g/ml) and 3.5-fold (from 0.06 to
0.21 g/ml) in FA6140. The penA35 allele conferred even
larger increases in the MIC of cefixime: 100-fold in FA19
(from 0.001 to 0.1 g/ml) and 10-fold in FA6140 (from 0.048 to
0.5 g/ml). Importantly, the MICs of ceftriaxone and cefixime
for FA19 penA35, although they were markedly increased over
those for FA19, were still substantially lower than their respec-
tive MICs for 35/02 (especially for ceftriaxone), demonstrating
that other resistance determinants play a role in Cephi.
Strain 35/02 has all of the known resistance determinants
found in strain FA6140, i.e., penA, mtrR, penB, and ponA1 (19).
Although the sequences of the penA genes are markedly dif-
ferent, the sequences of the mtrR and ponA1 determinants in
the two strains are 100% identical, and the sequences of the
penB genes are over 95% identical, with 100% identity within
loop 3, which contains the amino acids most relevant for con-
ferring resistance (23). Thus, we expected that FA6140 penA35
and 35/02, which also have the same penA allele, would have
the same level of resistance to the -lactam antibiotics; how-
ever, the MICs of all three antibiotics for FA6140 penA35 were
approximately twofold greater than those for 35/02 (Fig. 1).
These data suggest either that FA6140 contains an additional
determinant(s) not present in 35/02 or that the unknown re-
FIG. 1. MICs of penicillin G, ceftriaxone, and cefixime for strains FA19 and FA6140 transformed with the mosaic penA35 gene from strain
35/02. The penA35 allele from the Cephi strain 35/02 was transformed into FA19 or FA6140, and the MICs of penicillin G, ceftriaxone, and cefixime
for the resulting strains were determined as described in Materials and Methods. The MICs represent the averages  standard deviations for at
least two transformants in a minimum of three independent experiments.
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sistance determinant(s) in FA6140 has a stronger phenotype
than that in 35/02.
Role of mtrR and penB in Cephi. The synergistic effects of
mtrR and penB on penicillin resistance have been well docu-
mented (24, 33, 37). When they are present individually in
strain FA19 penA4, these determinants have either a small
effect (mtrR) or no effect (penB) on the MIC of penicillin G,
whereas together they increase the MIC by 8- to 10-fold. To
examine the role of mtrR and penB in Cephi, we carried out a
stepwise transfer of the mtrR and penB alleles from strain 35/02
into strain FA19 penA35 (Table 1) and determined the MICs
of penicillin G, ceftriaxone, and cefixime for the resulting
transformants (Fig. 2). Consistent with previous results, the
transformation of mtrR into FA19 penA35 increased the MIC
of penicillin G 1.5-fold, and further acquisition of penB35
resulted in an additional fourfold increase in resistance. Trans-
fer of the mtrR gene into FA19 penA35 had little to no effect on
the MIC of ceftriaxone, but upon the further transfer of
penB35, the level of resistance increased about 2.5-fold. In
marked contrast to the other antibiotics, neither mtrR nor penB
increased the level of cefixime resistance above that for FA19
penA35.
Although overexpression of the MtrC-MtrD-MtrE efflux
pump (as a result of the mtrR promoter mutation) has only
minimal effects on the penicillin G resistance of strain FA19
penA35 (Fig. 2), the resistance to penicillin G is markedly
decreased when the MtrC-MtrD-MtrE efflux pump is inacti-
vated in a high-level-penicillin-resistant clinical strain, indicat-
ing that the efflux pump is a critical element of high-level
penicillin resistance (33). To investigate further the role of the
overexpressed MtrC-MtrD-MtrE efflux pump in Cephi, we
knocked out the efflux pump by transforming strains FA6140,
FA6140 penA35, and 35/02 with a construct of the mtrD gene
(16) disrupted by insertion of the kpt resistance gene
(mtrD::Kan) (Table 1). Inactivation of mtrD in all three strains
decreased the MIC of penicillin G nearly 16-fold (Fig. 3; Table
2), highlighting the importance of the MtrC-MtrD-MtrE efflux
pump in high-level penicillin resistance. Ceftriaxone interme-
diate resistance was slightly less dependent on the efflux pump,
with an approximately eightfold decrease in the MIC for all
three strains being detected when the pump was disrupted. In
contrast, the disruption of mtrD conferred a much smaller
decrease (two- to threefold) in the level of cefixime resistance,
which was consistent with the apparent lack of an effect of
either mtrR or penB on cefixime resistance, as described above
(Fig. 2).
In contrast to the role of mtrR, the role of penB in high-level
penicillin resistance is less clear. The synergism between mtrR
and penB suggests that at least part of the role of mtrR, in
addition to increasing the efflux of antibiotics, is to promote
the resistance phenotype of penB, which is silent in the absence
of mtrR (24). To distinguish between its role in efflux and the
activation of PenB, we reverted the penB gene of FA6140
penA35 back to the wild-type porB1bFA1090 gene by allelic
exchange and determined the MICs of penicillin G, ceftriax-
one, and cefixime for the resulting transformants. Reversion of
the penB allele back to the wild-type conferred consistent two-
to threefold decreases in the MICs of each of the three anti-
biotics (Fig. 3 and Table 2). For both penicillin G and ceftri-
axone, reversion of penB to wild-type porB1b did not decrease the
MIC as much as deletion of the MtrC-MtrD-MtrE efflux
pump, whereas for cefixime, both reversion to wild-type
porB1b and deletion of the efflux pump had similar effects on
the MICs.
Role of ponA1 in Cephi. We also investigated the role of
ponA1, which encodes PBP 1 containing a single missense
mutation (L421P), in Cephi either by transforming a third-level
transformant with ponA1 or by reverting the sequence of the
ponA1 allele in FA6140 penA35 and 35/02 back to the wild-type
sequence. As previously reported for penicillin resistance,
FIG. 2. MICs of penicillin G, ceftriaxone, and cefixime for stepwise transformants of penA35, mtrR, penB35, and ponA1 in strain FA19. To
create these strains, FA19 was transformed in a stepwise manner with PCR amplification products or plasmids with the indicated resistance
determinants from Cephi strain 35/02. The MICs of penicillin G, ceftriaxone, and cefixime for the resulting strains were determined as described
in Materials and Methods and represent the averages  standard deviations for at least two transformants in a minimum of three independent
experiments.
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transformation of ponA1 into a third-level transformant had no
appreciable effect on resistance to any of the three antibiotics
tested (Fig. 2). When the sequence of the ponA1 allele was
reverted back to the wild-type sequence in FA6140 penA35 and
35/02, the level of penicillin G resistance decreased twofold,
consistent with our previous data (Fig. 4) (28). However, re-
version of the ponA allele had little to no effect on ceftriaxone
or cefixime resistance. Thus, in contrast to high-level resistance
to penicillin, ponA1 appears to have little or no role in Cephi
(Fig. 4).
DISCUSSION
The data presented in this report provide insight into the
individual contributions of the mosaic penA35 allele and the
mtrR, penB, and ponA1 resistance determinants to Cephi. We
showed that mosaic penA alleles (e.g., penA35) play an impor-
tant role in Cephi but that the other determinants, with the
exception of ponA1, are also required. A useful way of exam-
ining the individual contributions of the penA35 allele versus
the contributions of the entire set of other determinants is to
compare the MICs of ceftriaxone and cefixime for three
strains: FA19, FA19 penA35, and FA6140 penA35 (Table 3).
FA19 is an antibiotic-susceptible strain that serves as the start-
ing point for transformation studies, FA19 penA35 shows the
increase in resistance due solely to the penA35 allele, and
FA6140 penA35 shows the sum of the effects of penA35 in the
presence of the complete set of determinants critical for high-
level penicillin resistance.
The MICs of both antibiotics increased 400-fold from
FA19 to FA6140 penA35 (Table 3), but how this 400-fold
increase was achieved was markedly different for the two an-
tibiotics. For ceftriaxone, transfer of the penA35 allele into
FA19 conferred a 20-fold increase in the MIC, while the ad-
ditional determinants in FA6140 caused another 20-fold in-
crease in MIC, for a total increase of 400-fold. Thus, the
mosaic penA allele and the other resistance determinants con-
tribute equally to the increase in the MIC for this antibiotic. In
contrast, transfer of penA35 into FA19 increased the MIC of
cefixime by 100-fold, while the other determinants in FA6140
caused only an additional 4-fold increase in the MIC. Thus,
while the overall increases in the MICs of the two antibiotics
are the same, it is clear that for cefixime, the penA35 allele is
the major factor in resistance, while for ceftriaxone, the addi-
tional determinants, which function at least in part by limiting
the concentration of the antibiotic in the periplasm, are as
important as the mosaic penA allele in increasing the MIC.
These data demonstrate the different modes by which these
two cephalosporins inhibit the growth of gonococci.
Our data can be compared to those reported by Takahata et
al. (32), who transformed FA1090 with mosaic penA constructs
and determined the MICs of a range of -lactam antibiotics. In
that study, the MICs of ceftriaxone and cefixime were in-
creased 4- and 15-fold, respectively, upon transfer of the entire
FIG. 3. Effects of deletion of the MtrC-MtrD-MtrE efflux pump or reversion of penB to the wild-type sequence in strains FA6140, FA6140
penA35, and 35/02 on the MICs of penicillin G, ceftriaxone, and cefixime. To investigate the individual contributions of mtrR and penB to Cephi,
FA6140, FA6140 penA35, and 35/02 were transformed with plasmids harboring mtrD insertionally inactivated with a kanamycin resistance cassette
or porB1b with a downstream erythromycin resistance cassette, and the MICs of the resulting transformants were determined as described in
Materials and Methods. The MICs represent the averages  standard deviations for at least two transformants in a minimum of three independent
experiments.
TABLE 2. Decreases in MICs of penicillin G, ceftriaxone, and cefixime upon reversion of penB or deletion of mtrD
Strain
Fold decrease in MICa
Penicillin G Ceftriaxone Cefixime
Par/wtPIB Par/mtrD Par/wtPIB Par/mtrD Par/wtPIB Par/mtrD
FA6140 2.3 15.7 4.4 10.7 2.3 4.5
FA6140 penA35 2.6 16.0 3.6 9.6 2.2 2.9
35/02 4.0 15.7 2.3 6.0 1.7 2.8
Avg fold decrease 2.9  0.9 15.8  0.2 3.4  1.1 8.8  2.4 2.1  0.3 3.4  0.9
a The average decreases were surprisingly consistent among the three strains. Par/wtPIB, ratio of the MIC for the parental strain to the MIC for the penB reversion
strain; Par/mtrD, ratio of the MIC for the parental strain to the MIC for the strain with the mtrD deletion.
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mosaic penA allele into FA1090. Those increases are signifi-
cantly lower than the increases reported here in FA19 (20- and
100-fold). The differences in the two studies in part may reflect
the fact that FA1090 contains a penA gene (NGO1542 of the
sequence with GenBank accession no. AE004969) with an
Asp345a codon insertion that decreases the rate of acylation of
PBP 2 with -lactams (29), which would increase the MIC for
the starting strain and thus lower the increase in the MIC for
the resulting mosaic penA transformant.
Ochiai et al. (22) determined the 50% inhibitory concentra-
tions of a range of antibiotics for inhibition of Bocillin FL (a
fluorescent -lactam) binding to purified PBP 2 variants from
two antibiotic-resistant strains, one with a penA allele similar to
that of strain FA6140 and the other with a penA allele similar
to that of strain 35/02. They reported that the 50% inhibitory
concentrations of ceftriaxone for the two PBP 2 variants were
not different, inferring that the mosaic penA allele plays little to
no role in ceftriaxone intermediate resistance. In contrast, our
data show that isogenic replacement of the nonmosaic penA
allele in FA6140 with the mosaic penA35 allele increases the
MIC of ceftriaxone fourfold, from 0.05 to 0.2 g/ml (Fig. 1).
These results clearly indicate that the mosaic penA35 confers
an increase in the ceftriaxone MIC over and above that con-
ferred by penA4. The reasons for this discrepancy are not clear
but may be due to the utilization of inhibition curves to define
inhibition instead of the derivation of k2/Ks acylation constants
for the various antibiotics. Although in vitro binding data are
useful for comparison of the effects of mutations on PBPs, we
believe that the analysis of isogenic strains created with resis-
tance alleles whose sequences are known is the most valid and
straightforward approach to examination of the contributions
of specific alleles in conferring resistance to antibiotics.
Comparison of the MICs of the three antibiotics for FA19
penA35 with or without mtrR and penB mutations reveals that
the contributions of these two determinants to resistance vary
depending upon the antibiotic (Fig. 2). Thus, transfer of both
mtrR and penB into FA19 penA35 increased the MIC of pen-
icillin G 6-fold and that of ceftriaxone 3.3-fold but had little to
no effect on the MIC of cefixime (Fig. 1). The latter result was
unexpected, as these determinants would be predicted to de-
crease the level of permeation of any antibiotic that enters the
periplasm through porin channels. Thus, these data suggest
either that cefixime does not diffuse into the periplasm through
porin channels or that such diffusion is not altered by penB
mutations. One obvious distinction of cefixime from penicillin
G and ceftriaxone is that cefixime has a 2 net charge at
neutral pH, whereas penicillin G and ceftriaxone have a 1 net
charge. The2 net charge may affect the permeation of ce-
fixime.
Our data also shed light on the dual roles of the mtrR
determinant on Cephi and highlight the different modes of
action of the three antibiotics. mtrR mutations affect resistance
in two ways: increased efflux of the antibiotic and activation of
penB mutations that decrease diffusion through porin chan-
nels. In contrast, penB mutations increase reistance only when
an mtrR mutation is present. Deletion of mtrD in FA6140
penA35 or 35/02 caused marked 16- and 8-fold decreases in the
MICs of penicillin G and ceftriaxone, respectively, whereas the
MIC of cefixime was less affected (three-fold decrease) (Fig. 3
and Table 2). Conversely, the reversion of the penB sequence
back to the wild-type porB1b sequence decreased the MICs of
all three antibiotics about the same: between two- and three-
fold. These data suggest that the increases in resistance to
penicillin and ceftriaxone upon the acquisition of the mtrR and
penB determinants are due to a combination of efflux by the
MtrC-MtrD-MtrE pump and a decrease in permeation
through porins. In contrast, the mtrR mutation appears to
FIG. 4. Effects of reverting the ponA1 sequence to the wild-type ponA sequence in strains FA6140 penA35 and 35/02 on the MICs of penicillin
G, ceftriaxone, and cefixime. The ponA1 gene sequence was reverted to the wild-type ponA sequence by transformation with a plasmid harboring
the wild-type ponA sequence with a downstream spectinomycin and streptomycin resistance cassette, and the MICs of the resulting transformants
were determined as described in Materials and Methods. The MICs represent the averages  standard deviations for at least two transformants
in a minimum of three independent experiments.












FA19 penA35 0.012 20 0.12 100
FA6140 penA35 0.24 20 0.5 4.2
FA19 3 FA6140 penA35 400 420
a The MICs of ceftriaxone and cefixime for FA19 (which is an antibiotic-
susceptible strain), FA19 penA35 (which has an increase in resistance solely
because of the penA35 allele), and FA6140 penA35 (which has an increase in
resistance because of both penA35 and other resistance determinants) are shown.
b The increase was determined by dividing the MIC for the indicated strain by
the MIC for FA19.
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contribute to cefixime resistance solely by activating penB,
since the decreases in MICs following the inactivation of mtrD
and the reversion of the penB sequence to the wild-type se-
quence were highly similar. The fact that these genetic manip-
ulations had any effect at all was surprising, since we were
unable to observe a change in the MIC of cefixime when mtrR
and penB were transferred into FA19 penA35 (Fig. 3). The
reason for this discrepancy is not known, but it may reflect the
influence of the unknown determinant in FA6140 on both
the efflux pump and PenB.
Unlike previous studies, which associated penA35, mtrR,
penB, and ponA1 with Cephi through epidemiological and se-
quencing studies (19, 36), this study directly establishes the
contributions of these resistance determinants in Cephi. How-
ever, these determinants were not sufficient to increase the
MICs of any of the three antibiotics to donor levels when they
were transformed into strain FA19. Attempts to transform the
level of resistance of FA19 penA35 mtrR penB ponA1 to donor
levels with 35/02 or FA6140 genomic DNA were unsuccessful
(data not shown). These data on penicillin resistance are iden-
tical to those previously observed by us and others and suggest
the presence of an unknown determinant(s) that is nontrans-
ferrable by transformation and that modulates increased levels
of resistance (10, 28).
The role of ponA1 in high-level penicillin resistance is well
established, as shown by the twofold decrease in the MIC upon
the reversion of the ponA1 sequence to the ponA wild-type
sequence (Fig. 4) (28). However, no such decrease in the MIC
was observed for ceftriaxone or cefixime, indicating that ponA1
plays little to no role in resistance to these two antibiotics. This
distinction may reflect the differences in the rates of acylation
of the two essential PBPs, PBP 1 and PBP 2, by the three
antibiotics. For the wild-type PBPs, PBP 2 has an 16-fold
higher acylation rate with penicillin G than PBP 1 (2, 28),
making PBP 2 the primary lethal target for this antibiotic in
wild-type strains. Upon acquisition of the penA allele, the rate
of acylation of PBP 2 decreases by 16-fold, bringing it much
closer to that of PBP 1 (although PBP 2 is still the lethal target,
since the introduction of an altered PBP 1 with a lower rate of
acylation for the antibiotic does not increase the MIC of pen-
icillin). Upon acquisition of the other resistance determinants,
the lethal target of penicillin must shift to include PBP 1, and
thus, acquisition of an altered PBP 1 increases the MIC. For
the cephalosporins, we suspect that there may be much larger
differences in their rates of acylation of PBP 2 compared to
those of PBP 1, such that even with the decrease in the rate of
acylation of mosaic PBP 2 with the cephalosporins and the
presence of the other resistance determinants, PBP 1 never
becomes a lethal target, and accordingly, alterations in PBP 1
have no effect on resistance. Experiments to examine the rates
of acylation of the various wild-type and mutant PBPs with the
three antibiotics to test this possibility are in progress.
In conclusion, the present study clearly emphasizes that the
mosaic penA allele, mtrR, penB, and an unknown mutation, but
not ponA1, are important determinants for conferring inter-
mediate resistance to the expanded-spectrum cephalosporins
ceftriaxone and cefixime. Together, these determinants confer
400-fold increases in the MICs of both antibiotics but do so in
different ways: the mosaic penA allele and the set of other
resistance determinants contribute equally to resistance to
ceftriaxone, while the mosaic penA allele confers the greatest
increase in resistance to cefixime. The inability of ponA1 to
confer resistance to strain 35/02 or strain FA6140 penA35, even
though it is found in a wide range of Cephi strains (19), sug-
gests that these strains did not arise de novo from antibiotic-
sensitive strains but likely arose by transfer of mosaic penA
alleles into preexisting chromosomally mediated penicillin-re-
sistant strains, which persist in the bacterial population, even
though penicillin has not been recommended for use for the
treatment of gonorrhea for nearly 25 years (4). This would
explain the presence of the ponA1 allele, which is required for
high-level penicillin resistance, in almost all Cephi strains, even
though it does not contribute to Cephi. Such a mechanism
would also account for the rapid emergence of these strains
over the last several years. The current MIC breakpoint for
strains considered resistant to either ceftriaxone or cefixime
is 	0.25 g/ml. Given the documented ability of N. gonor-
rhoeae to acquire additional mechanisms of resistance to -lac-
tam antibiotics, it appears to be a matter of when and not if
strains resistant to these antibiotics will emerge, and when they
do, the dearth of other antibiotics useful for the treatment
of gonococcal infections portends a looming public health
problem.
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